butyryl-n-trihexylcitrate has been researched along with Coronary Restenosis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Almalla, M; Burgmaier, M; Reith, S; Schröder, J; Vogt, F | 1 |
Bruno, H; Erglis, A; Graf, K; Hehrlein, C; Hoffman, S; Kornowski, R; Merkely, B; Naber, C; Richardt, G; Slagboom, T; Toelg, R; Witzenbichler, B | 1 |
2 other study(ies) available for butyryl-n-trihexylcitrate and Coronary Restenosis
Article | Year |
---|---|
Long-term clinical outcomes after treatment of stent restenosis with two drug-coated balloons.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Butyrates; Cardiac Catheters; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Equipment Design; Excipients; Female; Humans; Iohexol; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Butyrates; Coronary Restenosis; Excipients; Female; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Registries | 2014 |